Jardiance Cost in California 2026: Prices, Insurance, Medicaid, and Compounded Options

What Is Jardiance and Why Does the Price Matter?

Jardiance is the brand name for empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA for type 2 diabetes, heart failure, and chronic kidney disease. It blocks renal glucose reabsorption, lowering blood sugar and reducing cardiovascular risk through mechanisms that go beyond glycemic control alone. The price matters because at $680 per month without assistance, annual spending tops $8,000, a figure that pushes many California patients to skip doses or abandon therapy entirely.

The EMPA-REG OUTCOME trial (N=7,020) demonstrated that empagliflozin 10 mg or 25 mg reduced the primary three-point MACE composite by 14% vs. placebo (HR 0.86; 95% CI 0.74-0.99; P<0.001 for non-inferiority, P=0.04 for superiority) and cut cardiovascular death by 38% (HR 0.62; 95% CI 0.49-0.77; P<0.001) [1]. That cardiovascular mortality signal transformed empagliflozin from a glucose-lowering agent into a first-line cardiometabolic drug, which explains why guidelines now prioritize it regardless of A1c.

The American Diabetes Association's 2024 Standards of Care state: "In patients with type 2 diabetes and established cardiovascular disease, SGLT2 inhibitors with demonstrated cardiovascular benefit are recommended as part of the glucose-lowering regimen independent of A1c" [2]. Because the benefit is cardiovascular as much as glycemic, Medi-Cal and most private insurers in California now list empagliflozin under both diabetes and cardiology formulary categories.

The FDA's current prescribing label covers type 2 diabetes management, reducing major adverse cardiovascular events in adults with T2D and established cardiovascular disease, heart failure (HFrEF and HFpEF), and reducing eGFR decline in CKD [3]. Each additional indication creates a separate prior-authorization pathway in California, which is critical to know before you call your insurer.

Jardiance Retail Price in California in 2026

The manufacturer list price sits at approximately $680 per 30-day supply at California retail pharmacies in 2026, covering both the 10 mg and 25 mg strengths. That figure is the average wholesale price before any insurance negotiation, coupon, or manufacturer rebate reduces it.

Cash-pay patients at major California chains, including CVS, Walgreens, Rite Aid, and independent pharmacies, typically see prices ranging from $655 to $720 depending on the dispensing pharmacy and whether they use a third-party discount card. GoodRx and similar platforms negotiate rates that may bring the cost to $580-$640 for the 25 mg strength, still well above the threshold where most patients can sustain therapy long-term [4].

No FDA-approved generic empagliflozin exists as of mid-2025 [3]. The core empagliflozin patents held by Boehringer Ingelheim do not expire until the late 2020s, meaning the cash price is unlikely to drop sharply through generic competition within the next two to three years. Patients who qualify for no-cost compounded empagliflozin through a licensed 503A pharmacy represent the most dramatic cost reduction available today.

A published health-economic analysis in Diabetes Care found that SGLT2 inhibitor therapy was cost-effective at a $150,000 per quality-adjusted life-year threshold for patients with established cardiovascular disease, which partly explains insurer willingness to cover the drug when documentation is in order [5]. Still, patients without insurance or with high-deductible plans feel the full $680 hit each month.

Medi-Cal (California Medicaid) Coverage for Jardiance

Medi-Cal covers empagliflozin with prior authorization across three principal indications: type 2 diabetes, heart failure, and chronic kidney disease. The prior authorization requirement applies to all three indications as of the 2025-2026 Medi-Cal Drug List, but approval rates are high when prescribers submit complete clinical documentation.

For type 2 diabetes, Medi-Cal typically requires documentation of an A1c above 7.0%, confirmation that the patient has tried at least one first-line agent (usually metformin), and notation of any cardiovascular or renal comorbidities. For heart failure, left ventricular ejection fraction documentation or a recent echocardiogram report satisfies the clinical-necessity requirement. For CKD, an eGFR between 20 and 45 mL/min/1.73m2 combined with a urine albumin-to-creatinine ratio above 200 mg/g is the standard threshold that triggers coverage.

The EMPEROR-Reduced trial (N=3,730) showed empagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 25% vs. placebo (HR 0.75; 95% CI 0.65-0.86; P<0.001), a finding that directly supported Medi-Cal's coverage expansion to heart failure patients [6]. The EMPEROR-Preserved trial (N=5,988) extended that evidence to heart failure with preserved ejection fraction, with a 21% reduction in the primary composite endpoint (HR 0.79; 95% CI 0.69-0.90; P<0.001) [7].

The EMPA-KIDNEY trial (N=6,609) confirmed a 28% reduction in the composite of kidney disease progression or cardiovascular death (HR 0.72; 95% CI 0.64-0.82; P<0.001) and was stopped early due to clear efficacy, reinforcing the CKD indication that Medi-Cal now covers [8]. Submitting trial references alongside clinical notes can accelerate prior authorization approvals with some Medi-Cal managed care plans.

Medi-Cal managed care plans, including Anthem Blue Cross of CA, Health Net, Molina Healthcare, and Kaiser Permanente's Medi-Cal product, each administer their own PA process. Response times vary from 24 hours in urgent cases to 14 business days for standard requests under California law [9]. Patients denied coverage have the right to a fair hearing through the California Department of Health Care Services.

Commercial Insurance Coverage for Jardiance in California

Most major commercial insurance plans operating in California include empagliflozin on their formulary at Tier 3 or Tier 4, meaning copays without assistance run $60-$200 per month depending on the plan design. Plans subject to the ACA's essential health benefits rules must cover prescription drugs, but they retain wide discretion over tier placement.

Covered California marketplace plans from Anthem Blue Cross, Blue Shield of California, Kaiser Permanente, and Molina Healthcare all list empagliflozin on their 2025-2026 formularies, though step-therapy requirements frequently apply. Step therapy means the insurer requires documentation that you tried metformin or a sulfonylurea first, unless cardiovascular or renal disease is documented.

Large employer-sponsored plans in California that use PBMs such as CVS Caremark, Express Scripts, or OptumRx negotiate net prices substantially below list, typically $300-$450 per month before copay. The patient's share depends entirely on the plan's cost-sharing structure. Many employer plans cap specialty tier copays at $150 per fill after the deductible is met.

Medicare Part D plans in California place Jardiance on Tier 4 or Tier 5. The Inflation Reduction Act's $2,000 out-of-pocket cap for Medicare Part D, effective January 2025, limits annual spending regardless of tier, making Medicare Part D one of the more affordable coverage pathways for older Californians who qualify [10].

The Boehringer Ingelheim and Lilly Savings Card

Boehringer Ingelheim and Eli Lilly co-market Jardiance and jointly offer a copay savings card for commercially insured patients. Eligible patients pay as little as $10 per month on qualifying prescriptions, with Boehringer Ingelheim covering up to $150 per fill for a maximum of 12 fills per calendar year.

The savings card is not available to patients covered by federal programs including Medicare, Medicaid, TRICARE, or any other government-funded plan. In California, that exclusion affects Medi-Cal enrollees and dual-eligible patients, who must rely on Medi-Cal's negotiated pricing instead.

Enrollment takes under five minutes at the Jardiance manufacturer website. The prescribing clinician or the patient's pharmacist can process the card at the point of sale with no prior approval. The card activates immediately and applies to both the 10 mg and 25 mg strengths at any retail pharmacy in California that participates in standard third-party billing.

Patients who lose commercial insurance mid-year, for example due to a job change, lose savings card eligibility at the same time. Planning ahead, including exploring a Covered California marketplace plan with a January 1 effective date during open enrollment, keeps the savings card accessible and avoids the gap between employer coverage and Medi-Cal enrollment.

Compounded Empagliflozin in California: What Is Legal?

Compounded empagliflozin from a California-licensed 503A pharmacy is legal under current state and federal law, subject to specific conditions. 503A pharmacies compound for individual patients based on a valid prescription from a licensed prescriber, using FDA-approved bulk pharmaceutical ingredients where available.

California's State Board of Pharmacy oversees 503A pharmacies and requires them to comply with USP 795 standards for non-sterile compounding [11]. Empagliflozin is a non-sterile oral compound, so 503A pharmacies may legally prepare it provided the prescriber determines that the compounded product serves a specific patient need not met by the commercially available Jardiance tablets.

The FDA's current position is that compounding a copy of a commercially available drug is generally not appropriate under section 503A of the Federal Food, Drug, and Cosmetic Act, except when a patient has a documented allergy to an inactive ingredient or a specific clinical need the commercial product cannot address [12]. In practice, California prescribers cite cost-related clinical necessity, documented intolerance to inactive excipients, or need for an alternative dose strength to justify the prescription.

Compounded empagliflozin costs vary widely by pharmacy and formulation, but patients at HealthRX-affiliated 503A pharmacies have accessed empagliflozin for costs substantially below the $680 retail list price. The legal and regulatory status may shift if the FDA designates empagliflozin as a drug that cannot be compounded under 503A, so patients should confirm current status with their prescriber before starting.

HealthRX 503A Candidacy Framework for Compounded Empagliflozin in California:

A patient is a reasonable 503A candidate when all three of the following are true: (1) documented inability to afford commercial Jardiance after applying all available savings programs, (2) a specific clinical need that a 503A formulation addresses (alternative dose, excipient sensitivity, or prescriber-verified cost-related nonadherence risk), and (3) a California-licensed prescriber willing to document the medical necessity in the chart. Patients who have Medicare or Medi-Cal as their primary payer require additional scrutiny because federal anti-kickback rules apply to pharmaceutical benefits in those programs.

Telehealth Prescribing of Jardiance in California

California permits telehealth prescribing of empagliflozin for established patients and, in many clinical contexts, for new patients completing a synchronous video or telephone visit. The state's telehealth framework under Health and Safety Code Section 1374.13 requires that the prescriber establish a valid patient-physician relationship before prescribing, which a synchronous video visit satisfies [13].

The COVID-era flexibilities that allowed prescribing via asynchronous questionnaire for certain controlled substances do not apply to empagliflozin, since it is not a controlled substance. Clinicians may prescribe it based on an asynchronous intake if their clinical judgment and professional licensing board guidelines permit it, but most California telehealth platforms use synchronous video to minimize liability.

Once prescribed, the California prescription is valid at any licensed pharmacy in the state. The prescriber can send it electronically to a retail pharmacy, a mail-order pharmacy, or a 503A compounding pharmacy, depending on what was discussed during the visit. Telehealth visits at HealthRX include metabolic lab review, A1c interpretation, and cardiovascular risk stratification before empagliflozin is prescribed.

The American Diabetes Association notes that access to care, including telehealth access, directly affects medication adherence and glycemic outcomes in underserved populations [2]. A California telehealth visit removes transportation barriers for patients in rural counties like Shasta, Siskiyou, and Trinity, where endocrinology wait times exceed six months.

Clinical Indications and Dosing Reference

Empagliflozin is dosed once daily, orally, with or without food. The FDA-approved starting dose for type 2 diabetes is 10 mg once daily in the morning, with uptitration to 25 mg once daily for additional glycemic benefit in patients who tolerate the lower dose [3]. For heart failure, the approved dose is 10 mg once daily regardless of ejection fraction. For CKD, the approved dose is 10 mg once daily, with an option to uptitrate to 25 mg in patients with eGFR at or above 45 mL/min/1.73m2.

Empagliflozin should not be initiated in patients with eGFR <30 mL/min/1.73m2 for glycemic control, though the CKD indication permits use down to eGFR 20 mL/min/1.73m2 for cardiorenal protection. Temporary discontinuation is recommended before major surgery, contrast procedures, and during prolonged fasting due to the risk of euglycemic diabetic ketoacidosis [3].

The EMPA-KIDNEY trial enrolled patients with eGFR as low as 20 mL/min/1.73m2, confirming safety and efficacy in advanced CKD, a population previously excluded from most SGLT2 inhibitor trials [8]. That finding has changed prescribing practice in California nephrology practices, where empagliflozin is now used in dialysis-preparation protocols at some academic centers.

Common adverse effects include genital mycotic infections (roughly 6% of women and 3% of men in clinical trials), urinary tract infections, and volume depletion, particularly in elderly patients on diuretics [3]. Fournier's gangrene and lower-limb amputations have been reported with SGLT2 inhibitors as a class; Jardiance's FDA label carries a warning for these rare events [3].

Comparing Empagliflozin to Other SGLT2 Inhibitors on Cost and Coverage

Three SGLT2 inhibitors dominate the California market: empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana). All three carry similar list prices, roughly $600-$720 per month for the branded versions. None has an FDA-approved generic as of 2025 [3].

Formulary placement differs by plan. Some California Medi-Cal managed care organizations prefer dapagliflozin for heart failure because the DAPA-HF trial (N=4,744) reported a 26% relative risk reduction in the primary composite endpoint (HR 0.74; 95% CI 0.65-0.85; P<0.001) and dapagliflozin was the first SGLT2 inhibitor to gain FDA approval for HFrEF in 2020 [14]. Patients whose Medi-Cal plan prefers dapagliflozin may face an easier prior authorization process for Farxiga than for Jardiance, even though the clinical profiles are broadly similar.

The CREDENCE trial (N=4,401) established canagliflozin's renal benefits, showing a 30% reduction in the primary kidney composite endpoint (HR 0.70; 95% CI 0.59-0.82; P=0.00001), but canagliflozin carries a higher amputation risk signal than empagliflozin in post-marketing data [15]. Most California nephrology guidelines currently prefer empagliflozin or dapagliflozin for CKD patients with peripheral arterial disease.

When a specific SGLT2 inhibitor fails prior authorization, prescribers can request a formulary exception citing published cardiovascular outcome data. California law requires commercial insurers to provide an exception process, and most managed care plans have a 72-hour turnaround for urgent exception requests [9].

Step-by-Step: Getting the Lowest Jardiance Cost in California

Start with insurance verification. Call the member services number on your insurance card and ask specifically whether empagliflozin is on the formulary, what tier it sits on, and whether step therapy applies. Document the representative's name and the date of the call.

If you have commercial insurance, apply for the Boehringer Ingelheim and Lilly savings card before your first fill. The card reduces your copay to as low as $10 per month and takes about five minutes to activate online or by phone.

If you have Medi-Cal, ask your prescriber to submit a prior authorization with documentation of your primary indication (T2D, heart failure, or CKD) and any relevant lab values. A1c, eGFR, echocardiogram results, and a brief cardiovascular history are the documents that move PA requests fastest.

If you are uninsured or the cash price is prohibitive, consult a telehealth clinician about whether a 503A compounding pharmacy is appropriate for your clinical situation. Not every patient qualifies under the HealthRX 503A Candidacy Framework above, but those who do may access empagliflozin at a fraction of the retail cost.

If you have Medicare Part D, check whether your plan's 2025 formulary lists Jardiance. The $2,000 annual out-of-pocket cap under the Inflation Reduction Act significantly reduces total exposure compared to prior years [10]. A Medicare Part D plan comparison at Medicare.gov takes roughly 15 minutes and shows real-time tier placement and estimated annual costs for your specific medications.

Patients who have been denied coverage should request a written explanation of the denial, then ask their prescriber to file an appeal citing the EMPA-REG OUTCOME, EMPEROR-Reduced, or EMPA-KIDNEY trial data directly in the appeal letter. In California, commercial insurers must respond to standard appeals within 30 days and expedited appeals within 72 hours [9].